Missouri is currently home to 1898 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Development of Novel Psychological Assessment Tools and Anxiety Intervention for Phenylketonuria
NCT06560736
Recruiting
While previous PKU intervention research has largely focused on pharmacological treatment of elevated Phe levels, the adaptation of evidence-based psychosocial therapy holds promise for addressing cognitive and psychological symptoms and significantly improving quality of life. Study goals include: (1) to demonstrate the efficacy and feasibility of a short-term skills-based intervention (Show Me FIRST) for anxiety and depression in adolescents with PKU, and (2) to further establish the psychomet... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
10/10/2024
Locations: University of Missouri, Columbia, Missouri
Conditions: Phenylketonurias
Register for Updates
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
NCT06099665
Recruiting
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Saint Luke's Health System, Kansas City, Missouri
Conditions: Aortic Valve Stenosis, Mitral Regurgitation
Register for Updates
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
NCT06361836
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/09/2024
Locations: SLUCare Academic Pavillion, Saint Louis, Missouri
Conditions: Hidradenitis Suppurativa
Register for Updates
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
NCT04986657
Recruiting
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Whole Genome Sequencing, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: St. Louis Heart and Vascular, Bridgeton, Missouri
Conditions: Heart Failure
Register for Updates
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT06582849
Recruiting
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing \>10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants to historic controls.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with bud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Washington University-School of Medicine /ID# 262943, Saint Louis, Missouri
Conditions: Solid Tumors
Register for Updates
Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
NCT04919018
Recruiting
Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often identified as most problematic by patients and their families, and optimal, highly effective treatment regimens have not been established. The main objective of this project is to characterize and co... Read More
Gender:
ALL
Ages:
Between 5 years and 45 years
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Primary Ciliary Dyskinesia, Kartagener Syndrome, Primary Immune Deficiency
Register for Updates
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
NCT04702243
Recruiting
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
Gender:
ALL
Ages:
Between 5 years and 45 years
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Primary Ciliary Dyskinesia, Primary Immune Deficiency, Kartagener Syndrome
Register for Updates
Targeted Lifestyle Change Group Prenatal Care
NCT04090307
Recruiting
To conduct a randomized trial to determine the effect of Targeted Lifestyle Change Group Prenatal Care (TLC) on maternal and neonatal outcomes in women at high risk for developing gestational diabetes mellitus (GDM).
Gender:
FEMALE
Ages:
13 years and above
Trial Updated:
10/07/2024
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Pregnancy, Gestational Diabetes
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Saint Louis University, Saint Louis, Missouri
Conditions: Giant Cell Tumor of Bone
Register for Updates
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
NCT05618301
Recruiting
Hematopoietic stem cell (HSC)-based gene therapies now offer curative potential for patients with sickle cell disease (SCD), with decreased toxicity compared to allogeneic hematopoietic cell transplantation. However, effective HSC-based gene therapy depends on collecting sufficient HSCs to generate the therapeutic product, and currently available mobilization regimens carry unacceptable risk for patients with SCD or do not reliably yield optimal numbers of HSCs for gene therapy. The investigato... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Sickle Cell Disease
Register for Updates